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A Ab bs st tr ra ac ct t
A variety of techniques that specifically target human gene sequences for differential capture from
a genomic sample, coupled with next-generation, massively parallel DNA sequencing instruments,
is rapidly supplanting the combination of polymerase chain reaction and capillary sequencing to
discover coding variants in medically relevant samples. These studies are most appropriate for the
sample numbers necessary to identify both common and rare single nucleotide variants, as well as
small insertion or deletion events, which may cause complex inherited diseases. The same
massively parallel sequencers are simultaneously being used for whole-genome resequencing and
comprehensive, genome-wide variant discovery in studies of somatic diseases such as cancer. Viral
and microbial researchers are using next-generation sequences to identify unknown etiologic
agents in human diseases, to study the viral and microbial species that occupy surfaces of the
human body, and to inform the clinical management of chronic infectious diseases such as human
immunodeficiency virus (HIV). Taken together, these approaches are dramatically accelerating the
pace of human disease research and are already impacting patient care.
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The human genome lies at the core of research into human
disease. New technologies for obtaining genome sequence
data are being combined with novel bioinformatics analyses
to characterize disease samples of many types, in the hope of
enhancing our fundamental understanding of susceptibility
and onset for inherited diseases, of the somatic changes that
take place to initiate cancers and cause metastatic disease,
and of the identity and allelic spectra of pathogenic and
commensal microbes that infect humans. These sequencing-
based discoveries will have a major impact on medical
practice, including the development of diagnostic and
prognostic assays, the identification of altered proteins to
which targeted therapies may be developed, the ability to
predict onset and severity of disease, and an improved
capability to predict our range of responses to pathogenic
agents. They will also create large datasets that effectively
identify each patient by their sequence information,
establishing the potential of linking a patient to a disease
and heightening the need to safeguard the privacy of these
data through legislation against genetic discrimination.
Inherited complex diseases have proved the most pervasive
yet recalcitrant examples of human disease to reveal their
genomic secrets. From a standpoint of statistical
significance, studying inherited disease at the genomic level
requires large numbers (ideally thousands) of cases
(affected) versus controls (unaffected) to uncover initial
findings, as well as the replication of any primary discoveriesin other case-control cohorts to solidify the association of a
given genomic variant(s) with disease. Although genome-
wide association studies (GWAS) have been broadly applied
across the spectrum of hypertension, diabetes, autism and
other diseases, the identification of disease-associated genes
by GWAS has so far identified mainly genes of low effect size
or within regions of the genome that do not contain
annotated genes, hence making it difficult to assign
functionality or even putative causality. With the
development and publication of several methods that can
selectively isolate sequences of interest from a genomic DNA
sample, there are now high-throughput methods available
for variant discovery within genomic regions identified by
GWAS or by candidate gene approaches. These methods use
a variety of solid-phase [1,2] or solution-phase [3] strategies
to capture the desired loci, typically isolating DNA fragments
that represent hundreds to thousands of genes in a single
experiment, which are then sequenced using next-
generation sequencing technology. Downstream variant
discovery aligns the sequences obtained to the targeted
regions or genes, and then identifies high-quality sequence
differences. A secondary level of interpretation can identify
those variants encoding a different amino acid or a
premature stop codon likely to impact the structure and
function of the proteins containing them. This exercise can
provide clues about which modified proteins may be
contributing to the disease biology. Combining the variant
information obtained across affected individuals with an
analysis of those cellular pathways in which the altered
proteins participate can then enable higher-level concepts to
emerge about disease biology.
All targeted capture methods are somewhat limited by the
fact that they rarely yield 100% coverage of the sequence
from any targeted region. As such, where coverage gaps exist
variants cannot be discovered, but this also occurs with
polymerase chain reaction (PCR)-based approaches. By
contrast, the combined targeted capture plus next-
generation sequencing generates data much faster, is more
scalable in terms of genes targeted and the ability to
combine patient samples into a single capture experiment,
and is cheaper than the conventional approach of PCR and
capillary sequencing. Moreover, because each next-
generation sequence read represents data from a single DNA
strand, the ability to discover sequence variants is greatly
facilitated over that of diploid PCR product sequences (both
alleles represented in the same reaction) obtained from a
capillary read. Targeted capture approaches are now being
applied to GWAS peaks for many inherited disease studies.
The resulting data will reveal the spectrum of rare single
nucleotide and insertion-deletion variants, and hopefully
will shed additional light on the genomic predisposition to
the disease of interest. Given the operational scale possible
for some of these methods (for example, solution-phase
capture can be carried out readily in a 96-well plate format)
and the massively parallel scale of next-generation
sequencing throughput, we will soon know whether this
predicted efficacy yields the promised rare variant
discoveries. However, the limited representation of the
human genome on single nucleotide polymorphism (SNP)
arrays will not provide a complete picture of case-specific
variation via GWAS. Rather, as the price of whole-genome
resequencing falls, so will the desire to fully characterize the
genomes of inherited, disease-affected individuals by whole
genome resequencing so that variant discovery is unbiased.
In contrast to inherited disease, somatic diseases such as
cancer do not typically require large sample numbers to
provide significant discovery potential. Both targeted
capture and whole-genome resequencing are currently
being used to study cancers of various types. Here, the list
of targeted genes typically is derived by a candidate-based
approach, which includes known cancer-associated genes
from studies of the particular tumor type, and may possibly
include genes lying under genomic regions determined to
have altered copy number (amplification or deletion) [4].
Studies to date using PCR and capillary sequencing have
essentially revealed that although many hundreds of genes
are sequenced, only a handful attain significant levels of
mutation across all samples studied. For example, in a
recent study of glioblastoma multiforme, The Cancer
Genome Atlas consortium reported that of 601 candidate
genes sequenced, only 223 revealed a mutation in at least
one of the 91 tumor samples studied and only eight genes
could be classified as significantly mutated [5]. Similarly,
when whole-genome resequencing was used to study an
acute myeloid leukemia (AML) genome and the genome of
its matched normal (skin) sample, the eight single-
nucleotide non-synonymous variants found were in genes
that essentially would never have been on a candidate gene
list for AML [6]. This early result has made a strong case for
whole-genome resequencing as an unbiased approach by
which medical research can pursue the genomic basis of
cancer. To date, we have been hindered by the cost of
whole-genome resequencing, but the falling cost of next-
generation sequencing experiments is quickly eliminating
this barrier, and hundreds of cancers will likely be
sequenced during 2009.
One interesting concept to note is that, using a variety of
DNA and RNA preparatory methods combined with next-
generation sequencing, one can produce sequence-based
characterizations of tumors that reveal the spectrum of
variation across the genome, the 'methylome' (that is,
cancer-specific changes in DNA methylation patterns), and
the transcriptome (expression levels of mRNA plus other
non-coding RNAs) in comparison to non-cancerous matched
tissue [7]. This wealth of data, when coupled with clinically
relevant information about the cancer (age of onset,
treatment history, outcome, family history/susceptibility,
and so on), provides the potential to more fully shape our
understanding of the disease biology. With similar analyses
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a correlated spectrum of affected genes, pathways, treatment
options and outcomes, including findings with translational
impacts on patient care, will begin to emerge. Only by
performing many such studies will we begin to understand
how individualized each cancer is, and hence shed light on
the importance of whole-genome versus targeted analysis of
cancers as a diagnostic or prognostic measure.
While cancer and inherited diseases are important
disorders to study using genomic data, the combination of
viral, bacterial and fungal pathogens adversely impacts
many more lives worldwide per year. Given the difficulty or
impossibility of culturing most pathogenic species, the use
of next-generation sequencing has greatly enabled their
identification. This typically is accomplished by isolating all
nucleic acids from a human sample (such as feces, tooth or
skin scrapings), sequencing the isolated DNA mixture, and
then assembling the non-human sequence reads to
reconstruct segments of the pathogenic genomes carried in
the sample. Next, these DNA sequences are translated into
amino acid sequences to help identify the novel pathogen(s)
and to characterize gene content and other attributes (such
as antibiotic resistance). Such 'metagenomic' studies
comprise some of the most exciting discovery-based science
happening in medical research today.
In terms of known pathogens, the exquisite sensitivity of
next-generation sequencing is already being applied to
disease management. One brilliant example of this is in
human immunodeficiency virus (HIV) disease
management, where newly diagnosed patients' sera are
input to PCRs that target specific viral genome regions,
allowing the clinician to assess the mutational status of each
viral population as a precursor to developing a patient-
specific drug cocktail. In essence, while there are over 20
HIV-specific therapies available, only by sequencing each
patient's viral population can therapies to which viral
resistance already exists be avoided [8].
It also remains unclear whether and how healthy
individuals interact with their natural commensal
bacterial, viral and eukaryotic species ('microbiome'), or
how changes to the normal prevalence of various species
(or strains) may influence our relative wellness. The NIH
Roadmap has set up a Human Microbiome Project [9] and
provided funding to begin to address such questions, as
well as to dramatically improve the census of sequenced
human microbiome species available in public databases.
These genomes will provide a tremendously enhanced
database for microbiome- and metagenomic-based queries,
furthering medical research in the process of answering the
question 'Who's there?' for different healthy and disease
states.
Cumulatively, the impact of next-generation sequencing on
medical research is beginning to gain momentum, and we
can already predict a point at which discoveries resulting
from the kind of inquiries described in this commentary
may overwhelm our abilities to translate them into clinical
applications. After all, sequencing data will provide a
multitude of clues, but few direct answers. To meet this
challenge, functional screening approaches must scale up to
high throughput and our characterization and annotation of
human genome functional elements must accelerate. We
need to find ways to engage colleagues familiar with
biochemistry, cell biology, medicine, pharmacology, and
other relevant fields to help interpret discoveries from next-
generation sequencing studies and to think about the next
steps. And, in an era of genomic data accessibility, we need
to ensure the privacy of would-be study volunteers so our
work proceeds without the delays that will occur if there is a
dearth of properly consented samples.
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AML, acute myeloid leukemia; GWAS, genome-wide
association studies; HIV, human immunodeficiency virus;
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